Dalian Bio-Chem addresses Shanghai Exchange concerns over 2024 report
Dalian Bio-Chem (the "Company") has released its response to the Shanghai Stock Exchange's regulatory inquiry regarding the 2024 annual report. A key area of focus was the industrial bactericide business, where revenue grew to CNY1.207 billion, representing 92% of total revenue, though the gross profit margin decreased by 8.28 percentage points. The company attributed this margin decline to decreased average selling prices amidst increased market supply, and increased shipping prices, despite effective cost management. The company provided detailed data on product pricing, sales volumes, and cost structures for the past three years, alongside comparisons to industry peers. Further clarification was given on top overseas clients, their sales, and relationships with Dalian Bio-Chem, along with overseas shipping arrangements.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Dalian Bio-Chem publishes news
Free account required • Unsubscribe anytime